210 related articles for article (PubMed ID: 35920441)
1. Precise epigenomic editing with a SunTag-based modular epigenetic toolkit.
Guhathakurta S; Adams L; Jeong I; Sivakumar A; Cha M; Bernardo Fiadeiro M; Hu HN; Kim YS
Epigenetics; 2022 Dec; 17(13):2075-2081. PubMed ID: 35920441
[TBL] [Abstract][Full Text] [Related]
2. Targeted Modification of Epigenetic Marks Using CRISPR/dCas9-SunTag-Based Modular Epigenetic Toolkit.
Song MK; Kim YS
Methods Mol Biol; 2024; 2761():81-91. PubMed ID: 38427231
[TBL] [Abstract][Full Text] [Related]
3. Regulation of Gene Expression Using dCas9-SunTag Platforms.
Morita S; Horii T; Hatada I
Methods Mol Biol; 2023; 2577():189-195. PubMed ID: 36173574
[TBL] [Abstract][Full Text] [Related]
4. A review on CRISPR/Cas-based epigenetic regulation in plants.
Jogam P; Sandhya D; Alok A; Peddaboina V; Allini VR; Zhang B
Int J Biol Macromol; 2022 Oct; 219():1261-1271. PubMed ID: 36057300
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas mediated epigenome editing for cancer therapy.
Ansari I; Chaturvedi A; Chitkara D; Singh S
Semin Cancer Biol; 2022 Aug; 83():570-583. PubMed ID: 33421620
[TBL] [Abstract][Full Text] [Related]
6. Editing of DNA Methylation Using dCas9-Peptide Repeat and scFv-TET1 Catalytic Domain Fusions.
Morita S; Horii T; Hatada I
Methods Mol Biol; 2018; 1767():419-428. PubMed ID: 29524149
[TBL] [Abstract][Full Text] [Related]
7. In vivo epigenome editing and transcriptional modulation using CRISPR technology.
Lau CH; Suh Y
Transgenic Res; 2018 Dec; 27(6):489-509. PubMed ID: 30284145
[TBL] [Abstract][Full Text] [Related]
8. Editing the Epigenome to Tackle Brain Disorders.
Liu XS; Jaenisch R
Trends Neurosci; 2019 Dec; 42(12):861-870. PubMed ID: 31706628
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic editing: Dissecting chromatin function in context.
Policarpi C; Dabin J; Hackett JA
Bioessays; 2021 May; 43(5):e2000316. PubMed ID: 33724509
[TBL] [Abstract][Full Text] [Related]
10. Targeting cancer epigenetics with CRISPR-dCAS9: Principles and prospects.
Rahman MM; Tollefsbol TO
Methods; 2021 Mar; 187():77-91. PubMed ID: 32315755
[TBL] [Abstract][Full Text] [Related]
11. Site-specific recruitment of epigenetic factors with a modular CRISPR/Cas system.
Anton T; Bultmann S
Nucleus; 2017 May; 8(3):279-286. PubMed ID: 28448738
[TBL] [Abstract][Full Text] [Related]
12. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells.
Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A
Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202
[TBL] [Abstract][Full Text] [Related]
13. Advances of epigenetic editing.
Gjaltema RAF; Rots MG
Curr Opin Chem Biol; 2020 Aug; 57():75-81. PubMed ID: 32619853
[TBL] [Abstract][Full Text] [Related]
14. DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A.
Huang YH; Su J; Lei Y; Brunetti L; Gundry MC; Zhang X; Jeong M; Li W; Goodell MA
Genome Biol; 2017 Sep; 18(1):176. PubMed ID: 28923089
[TBL] [Abstract][Full Text] [Related]
15. A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs.
Pflueger C; Tan D; Swain T; Nguyen T; Pflueger J; Nefzger C; Polo JM; Ford E; Lister R
Genome Res; 2018 Aug; 28(8):1193-1206. PubMed ID: 29907613
[TBL] [Abstract][Full Text] [Related]
16. Antagonistic and synergistic epigenetic modulation using orthologous CRISPR/dCas9-based modular system.
Josipović G; Tadić V; Klasić M; Zanki V; Bečeheli I; Chung F; Ghantous A; Keser T; Madunić J; Bošković M; Lauc G; Herceg Z; Vojta A; Zoldoš V
Nucleic Acids Res; 2019 Oct; 47(18):9637-9657. PubMed ID: 31410472
[TBL] [Abstract][Full Text] [Related]
17. Editing the Epigenome: Reshaping the Genomic Landscape.
Holtzman L; Gersbach CA
Annu Rev Genomics Hum Genet; 2018 Aug; 19():43-71. PubMed ID: 29852072
[TBL] [Abstract][Full Text] [Related]
18. Regulation of gene expression by altered promoter methylation using a CRISPR/Cas9-mediated epigenetic editing system.
Kang JG; Park JS; Ko JH; Kim YS
Sci Rep; 2019 Aug; 9(1):11960. PubMed ID: 31427598
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9 in epigenetics studies of health and disease.
Sar P; Dalai S
Prog Mol Biol Transl Sci; 2021; 181():309-343. PubMed ID: 34127198
[TBL] [Abstract][Full Text] [Related]
20. A Review on CRISPR-mediated Epigenome Editing: A Future Directive for Therapeutic Management of Cancer.
Chakravarti R; Lenka SK; Gautam A; Singh R; Ravichandiran V; Roy S; Ghosh D
Curr Drug Targets; 2022; 23(8):836-853. PubMed ID: 35078394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
